Technology ID
TAB-2792

Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays

E-Numbers
E-562-2013-0
Lead Inventor
Shu, Bo (CDC)
Co-Inventors
Lindstrom, Stephen (CDC)
Wu, Kai-Hui (CDC)
Berman, LaShondra (CDC)
Applications
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
Lead IC
CDC
ICs
CDC
This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. CDC researchers have developed a rapid, accurate, real-time RT-PCR assay that has several advantages over culture and serological tests, which require 5 to 14 days for completion; this assay can also be easily implemented in kit form. To date, hundreds of human cases of infection with the H3N2 variant virus have been confirmed. The increased numbers of human infection of H3N2 variant virus has led to a need for a highly sensitive and specific assay for the diagnosis and confirmation of the H3N2 variant virus.
Commercial Applications
  • Influenza diagnostic using clinical specimens
  • High-throughput sample screening
  • Government, regional influenza surveillance programs
Competitive Advantages
  • Especially useful for H3N2 screening
  • Sensitive detection
  • Specific discrimination of influenza subtypes
  • Easily formatted as kit or array
  • Faster than culturing and serological identification methods
  • Less laborious and more objective than immunoassays
Licensing Contact:
Mitzelfelt, Jeremiah
jeremiah.mitzelfelt@nih.gov